Human gamma2 contributes to heteromeric GABA-A receptor pore and allosteric architecture. Human alpha/beta/gamma2 structures and functional currents support the core channel role; orthosteric GABA recognition is principally at beta/alpha interfaces, while the alpha/gamma interface supports benzodiazepine modulation. Engineered loops, purification tags and chimeric assay components remain distinct from natural splice products (PMID29950725, PMID30602789).
Direct official sequences resolve long 475, short 467 and inserted-segment 515 products. PMID30602789 Methods explicitly uses the long P18507-2 backbone; a reference metadata range ending467 is not evidence that it used the short splice form. Selected native human-brain results identify gamma2 in major receptor assemblies, while a separate auxiliary map retains a gamma-x assignment. Mass spectrometry detects short and long forms without resolving the splice product of each map (PMID39843743).
Postsynaptic clustering and receptor trafficking are supported with assay-specific limits. Human receptor-containing cells form functional contacts in the reduced co-culture system, but gamma2 alone is not sufficient and the JoVE protocol reuses earlier material (PMID23909897, PMID25489750). Selected original neurexin Results explicitly place gamma2-containing clusters on dendritic surfaces, with MAP2 and live antibody labeling; the inspected Methods describe E18 rat hippocampal cultures. This supports location without assigning the neurexin/neuroligin synaptogenic step to gamma2 (PMID15620359).
Gamma2 association with KIF21B and transport-vesicle delivery supports a non-core trafficking pool, with full-method and imaging limits retained (PMID25172774). Rat gamma2 immunogold localization includes synaptic and lower-density extrasynaptic membrane, so gamma2 is not confined to synapses (PMID9464994). Histamine modulation depends on heteromer composition and differs from direct histamine gating of beta homomers; no gamma2 histamine-binding site is asserted (PMID18281286).
One human GABARAPL1 partner assertion remains unresolved: the original accessible abstract concerns GABARAP, and later mouse GABARAPL1/gamma2 experiments do not establish the original human context (PMID9892355, PMID33436612). The source-specific negative GABAergic-transmission NAS assertion is removed because the inspected review assigns the inhibitory trafficking step to accessory regulators acting on the receptor (PMID33234346). Other contexts were independently adjudicated; no evidence-code-wide rule or NEW process assertion was used.
The private review covers 74 original contexts: 46 ACCEPT, 14 KEEP_AS_NON_CORE, 12 MODIFY, 1 UNDECIDED and 1 REMOVE. It retains two original contributes_to relations, zero extension atoms, three natural products and one channel core. Nine refinements use is_a, two use part_of location relations and one refines complex composition semantically without claiming a missing ontology edge. The actual PAINT tree places all eight inherited assertions on the target lineage, with no retained target-path loss; the older incoming plasma-membrane donor subset remains unchanged.
The source guide records all 31 manual reference assessments and reading limits. Source caches and original contexts are immutable. These are prospective private files; no native target acquisition, history scaffold or target validation has yet run.
A genuine seeded fetch produced74 annotations and the same16-column export as the retained official inputs. All74 machine objects and individual review judgments match the accepted proposal; the two contributes_to qualifiers remain literal and there are no extension atoms. The displayed475-residue sequence and all three seeded product identities match the independently checked products. The native review identifier/type/status and two cached-title punctuation changes are the only transfer adaptations.
All41 normal sources are present: eight existing-main objects,20 exact published-source reuses and13 missing-only acquisitions. No immutable source was refreshed or rewritten. The12-word core quotation matches the actual PMID30602789 cache. The source guide distinguishes actual source availability from selected original, abstract-only and external reading scopes. Earlier prospective statements above describe the pre-native stage.
A genuine CREATE history was scaffolded and validated. Target validation passed with 20 advisories: three positive generic-binding contexts retained under the project policy and 17 optional per-row excerpt suggestions. Strict GOA validation confirms all 74 original annotations, and the status audit confirms DRAFT. Private rendering passed. Native 51 now records the verified term-scope propagation metadata for the postsynapse-to-membrane refinement, preserving the action and reason. The two native-generated ontology cache rows are reconciled to the exact published GABRA1 rows; all accepted-main rows and all 41 normal source bytes remain unchanged.
The earlier journal statement that KEEP_AS_NON_CORE for bare protein binding followed project policy was incorrect. The NOVA1, LHFPL4 and GABARAP associations remain supported within their respective assay limits, but their three generic GO:0005515 annotations are removed because they do not identify an informative molecular function of gamma2. This does not deny the interactions or assign a partner's RNA-processing, clustering or trafficking activity to gamma2. The distinct GABARAPL1 context remains UNDECIDED because its original source-specific evidence is unresolved (PMID:27733149(https://pubmed.ncbi.nlm.nih.gov/27733149/), PMID:28978485(https://pubmed.ncbi.nlm.nih.gov/28978485/), PMID:9892355(https://pubmed.ncbi.nlm.nih.gov/9892355/)).
The chloride-channel-complex annotation is now ACCEPT. Gamma2 is part of a chloride-conducting receptor assembly, and replacing that true claim with an already represented receptor-complex term is not justified by an empty ontology path query. The fresh query again returns no is_a/part_of path from GO:1902711 to GO:0034707; the missing relationship is raised as an ontology question. The original query and withdrawn replacement proposal remain traceable in the source evidence.
Three short exact core excerpts now support the M2 pore-lining contribution, beta/alpha GABA interfaces and alpha/gamma flumazenil interface (PMID:29950725(https://pmc.ncbi.nlm.nih.gov/articles/PMC6220708/), PMID:30602789(https://pmc.ncbi.nlm.nih.gov/articles/PMC6364807/)). Together with the unchanged receptor-identity quote, the totals are 21 and 24 words respectively. The source guide preserves construct and reading limits; this journal does not repeat the quoted text. The redundant plasma-membrane parent is removed only from the core location list, while source annotations and the evidence for other surface pools remain intact. The benzodiazepine activity stays non-core as a pharmacological context, and the existing biological questions and proposed experiments remain explicit.
Current actions are 47 ACCEPT, 11 KEEP_AS_NON_CORE, 11 MODIFY, 1 UNDECIDED and 4 REMOVE across all 74 original contexts, with no NEW annotation. All machine fields, two contributes_to relations, three natural products, source-access limits and 41 source caches remain unchanged. Earlier journal entries retain their historical counts and interpretations. Native EDIT history and scoped checks have completed for this amendment.
The native EDIT session is 2026-11-02T014412Z-codex-9ebbd9. Default validation passed with 17 optional suggestions for additional excerpts and no generic-binding advisories. Strict GOA matched all 74 contexts; status remains DRAFT. History, source conservation, scoped whitespace and private rendering passed. All 41 source files, three products, original source fields and the prior CREATE record remain unchanged. No provider or broad local test suite was run.